- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Asia Green Biotechnology
Optimizing CBD-Rich Hemp For Emerging Applications
Overview
Asia Green Biotechnology Corp (CSE:ASIA) is an agricultural technology corporation focused on the creation, cultivation, production and application of high-quality and specialized hemp strains in emerging Asian markets. The company is focused on five emerging use applications of hemp and hemp by-products: food, fibre, fuel, pharmaceutical and foundational materials. Driven by the global trend towards the legalization of cannabis, a new awareness of the versatility and viability of products derived from hemp is increasingly causing use of the plant and its by-products to be considered in a number of industrial applications.
Asia Green intends to pursue this opportunity by developing and offering a diverse range of hemp strains and hemp-derived products. In cooperation with its technical partners, the company is working to develop its organic hybridization technology which has the potential to lead to the development of new hemp-based products tailored for specific applicationss. Initially, Asia Green has established cultivation partnerships with a particular focus on Cambodia and Thailand in pursuit of low-cost cultivation conditions that have the potential to facilitate optimal hemp crop growth.
According to research conducted by Research and Markets, the global industrial hemp market is expected to grow at a compound annual growth rate of 34 percent from US$4.6 billion in 2019 to US$26.6 billion by 2025. The Asia Pacific region accounted for the largest amount of industrial hemp production in 2018, partly due to the area’s reliance on hemp as an input in the textile and paper industries. Asia Green believes the temperatures and balanced intervals of sunlight in certain regions of Asia are optimal for hemp cultivation, providing another potential competitive advantage over similar hemp producers.
As a renewable source material, hemp has the potential to reduce costs in industries capable of incorporating the plant into existing compounds and formulations. Asia Green is currently focused on developing strains that can be cultivated for specific needs including hemp-based foods, fibers, fuels and foundation materials. The company has secured a licensing agreement with InPlanta Biotechnology, a research and development team based in Alberta. InPlanta operates a state-of-the-art cannabis and hemp research and development facility in collaboration with research partners, licensed producers and government agencies at the University of Lethbridge.
Asia Green Biotechnology has also entered into an agreement with Swysh Inc, an Alberta company conducting cannabinoid-based research. The company owns proprietary technology and intellectual property related to the creation of topical treatments for a variety of ailments, including anti-viral and preventative healthcare applications. Under the terms of the agreement, Asia Green is participating in R&D activity based on Swysh’s intellectual property, enabling the company to test and market products derived from this research in the company’s licensed territories.
“Through the InPlanta license agreement, we have seen ACC expand its business activities in Asia in a positive way. By entering this license agreement with Swysh, we believe the Company will be in a position to significantly expand that activity with access to potential cannabinoid-based treatments and other elements which have the potential to be of significant benefit to populations of the region,” said Dr. Igor Kovalchuk, director of Asia Green. Dr. Kovalchuk is also a director and the controlling shareholder of Swysh.
Asia Green Biotechnology’s Company Highlights
- Proprietary organic hybridization technology allows for strains to be bred to produce specific traits optimized for common use-cases
- Partnered with InPlanta Biotechnology to develop hemp strains optimal for use as food, fuel, fiber, and foundation materials
- Global industrial hemp market expected to grow from US$4.6 billion in 2019 to US$26.6 billion by 2025 according to Research and Markets
- Asia Pacific region accounted for the largest amount of industrial hemp production in 2018
- Licensing agreement with Swysh, enabling Asia Green to participate in R&D activity based on Swysh’s intellectual property
Get access to more exclusive Biotech Stock profiles here.
Interactive Chart
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.